相关实验视频

Updated: Jun 11, 2025

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

阻断TSP1通过抑制TGF-β/SMAD通路来改善糖尿病引起的勃起功能障碍

Mancheng Xia^1,2,3,4, Yiming Yuan^1,2,3,4, Dong Fang^1,2,3,4

¹Department of Urology, Peking University First Hospital, Beijing, China.

The world journal of men's health

|September 30, 2024

概括

血栓松丁-1 (TSP1) 驱动糖尿病诱导勃起功能障碍 (DMED) 中的纤维化. TSP1抗剂LSKL通过阻断TGF-β/SMAD通路来改善勃起功能,提供了一个潜在的治疗标.

科学领域:

泌尿器科泌尿器科泌尿器科泌尿器科
内分泌学在内分泌学.
细胞生物学细胞生物学

背景情况:

糖尿病引起的勃起功能障碍 (DMED) 是一种复杂的疾病,通常涉及阴茎纤维化.
在DMED中纤维化背后的精确分子机制需要进一步阐明.
血栓蛋白-1 (TSP1) 已涉及纤维化过程,但其在DMED中的作用尚未完全理解.

研究的目的:

研究TSP1在DMED中纤维化发展中的作用和机制.
评估LSKL的治疗潜力,一个TSP1抗剂,在缓解DMED相关纤维化.

主要方法:

在使用链毒素的老鼠中诱导了DMED;治疗组包括对照组,DMED和使用LSKL的DMED.
用Sirius红色和Masson三色染色来评估阴茎纤维化.
在体外研究中,使用高葡萄糖诱导的体光滑肌细胞 (CCSMC) 和纤维细胞 (CCF) 治疗或不治疗LSKL来评估TSP1表达,TGF-β通路激活和通过西部斑点和免疫光来沉积原.

主要成果:

在DMED的老鼠中,洞内压力 (ICP) /平均动脉压 (MAP) 的比率下降,滑肌与原的比率发生变化,这表明有纤维化.
在DMED大鼠的体洞 (CC) 和HG治疗的CCSMC和CCF中,TSP1的表达显著升高.
在DMED大鼠中,LSKL治疗改善了ICP/MAP比率和原蛋白配置,并在CCSMC中抑制了HG诱导的TGF-β/SMAD通路激活和IV原蛋白过度表达.

结论:

在CC中TSP1表达的升高有助于DMED中的阴茎纤维化,可能是通过自身和副信号传递.
高葡萄糖条件激活TSP1分泌,通过TGF-β/SMAD通路促进纤维化.
通过对抗TSP1并抑制TGF-β/SMAD信号通路,LSKL显示了DMED的治疗潜力.

关键词:

糖尿病是一种糖尿病.勃起功能障碍是因为勃起功能障碍.纤维化纤维化纤维化转化增长因子β1的转化增长因子β1

更多相关视频

Visualization and Quantification of TGFβ/BMP/SMAD Signaling under Different Fluid Shear Stress Conditions using Proximity-Ligation-Assay

Visualization and Quantification of TGFβ/BMP/SMAD Signaling under Different Fluid Shear Stress Conditions using Proximity-Ligation-Assay

Published on: September 14, 2021

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

相关概念视频

TGF - β Signaling Pathway

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...